Karyopharm stock tumbles after Phase 3 Xpovio trial fails in endometrial cancer
read at Endpoints ↗Negative readoutNegative
Karyopharm announced that its Phase 3 XPORT-EC-042 study of Xpovio in endometrial cancer did not meet its primary endpoint.
The failure represents the company's second unsuccessful attempt to expand the blood‑cancer drug into a solid‑tumor indication, and the news sent the shares sharply lower.
Investors reacted negatively, with the stock price plunging after the announcement, underscoring the challenges of repurposing Xpovio for new cancer types.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer”
read at Endpoints ↗82 words · retrieved Jul 31
comments(0)
5-min edit window · permanent after that